Fully Humanized Monoclonal Antibodies: Engineering the Next Standard of Trust in Biologics
Fully humanized monoclonal antibodies are reshaping how developers design biologics-moving the field toward therapies that better balance potency with tolerability. By retaining the antibody framework closest to human sequences while replacing only the antigen-binding regions, these molecules aim to reduce immunogenicity risk compared with earlier antibody generations. In practical terms, that can translate into more …